Author: Healio ophthalmology

Specialist: Original AREDS formulation still best option for non-smokers

LISBON, Portugal — Because there are no safety issues in non-smokers exposed to beta-carotene, there is no reason why these patients should be switched to the AREDS2 formulation from the original AREDS formulation, according to one speaker at the Controversies in Ophthalmology meeting. In response to studies reporting an association between beta-carotene and increased risk of mortality and lung cancer, AREDS participants who were current smokers were reassigned to a formulation that did not contain beta-carotene. “At the conclusion of the AREDS, no increase in mortality or lung cancer was (Read more...)

New cross-linking protocol, device may help fight infectious keratitis on a global scale

LISBON, Portugal — An optimized treatment protocol, a miniaturized device that mounts on a slit lamp and a new photosensitizing agent may allow for a faster and more effective application of cross-linking for infectious keratitis in the near future. Cross-linking for infectious keratitis, now called PACK-CXL for photoactivated chromophore for keratitis-CXL, disinfects the corneal surface via reactive oxygen species and increases the resistance to enzymatic digestion by modification of the collagen structure.

Cost, accessibility remain issues for homebased monitoring of AMD

LISBON, Portugal — Daily home-based monitoring of age-related macular degeneration can have a positive impact on prompt, early treatment and preservation of vision, but access and cost may be issues, speakers said during a debate at the Controversies in Ophthalmology meeting. Susan B. Bressler, MD, PhD, presented results of the National Eye Institute’s HOME study, a secondary study to AREDS2, in which the ForeseeHome AMD Monitoring Program (Notal Vision) was used. The study was a 3-year phase 3 trial in which 1,520 participants were randomized 1:1 into the device group (Read more...)

Under-monitoring, under-treatment of AMD confirmed by real-life studies

LISBON, Portugal — Real-life studies carried out in different countries confirmed that age-related macular degeneration patients who require intravitreal anti-VEGF injections are under-monitored and under-treated. “Several studies already published, including LUMIERE, AURA, WAVE and Coimbra, as well as Medicare data, seem to indicate that this is the scenario all over the world,” Rufino Silva, MD, said at the Controversies in Ophthalmology meeting. The studies looked at the results of real-world clinical practice and revealed a scenario that is different from what should be expected by following the recommendations of clinical (Read more...)

Ocriplasmin injection showed high rate of success in select VMT patients

LISBON, Portugal — Real-life data of a selected, homogeneous group of patients with vitreomacular traction only, treated by a single injection of ocriplasmin, showed higher efficacy compared with MIVI-TRUST data. “We had an overall success rate, in terms of resolution of the traction, in 52% of the patients, compared with the 26% rate of the MIVI-TRUST. Patients with focal traction did even better, with a 61% success rate,” Peter Szurman, MD, said in an industry-sponsored symposium at the Controversies in Ophthalmology meeting.

Foveal bulges linked to better BCVA in eyes with resolved macular edema

The presence of a foveal bulge in healthy eyes and eyes with resolved macular edema associated with branch retinal vein occlusion may indicate better best corrected visual acuity, according to a study. The retrospective, observational case series included 31 eyes of patients with macular edema attributed to BRVO. A control group included 31 healthy fellow eyes. Through spectral-domain optical coherence tomography, researchers identified foveal bulges in all 31 eyes in the control group and in seven eyes in the BRVO group at final visit, a statistically significant difference (P